Clinical Trials Logo

Filter by:
NCT ID: NCT06047041 Recruiting - Mental Health Issue Clinical Trials

Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students

E-IMPACTS
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study will assess how different types of training and support influence the way that school staff understand, and respond to, the mental and behavioral health needs of middle school students. Researchers will work with middle schools using a developed screening system (called the Early Identification System; EIS) and compare how staff and student outcomes change when schools receive two different types of training and support: 1) standard onboarding/training versus 2) participating in professional learning communities and coaching.

NCT ID: NCT06047028 Recruiting - Clinical trials for Myocardial Perfusion Imaging

'Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

Start date: June 30, 2023
Phase:
Study type: Observational

Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.

NCT ID: NCT06046872 Recruiting - Clinical trials for Behavioral Shift (Researcher Willingness to Report-back)

Impacts of a Report-back Training Program

Start date: June 22, 2023
Phase: N/A
Study type: Interventional

Researchers participate in a hands-on training program on returning personal exposure results, and pre- and post-tests assess outcomes shifts in knowledge and perspectives on its value, and willingness to implement report-back in current or future studies.

NCT ID: NCT06046859 Recruiting - Clinical trials for Musculoskeletal Injury

Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

With this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent/mitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We also hypothesize that immediate use of Fluoxetine will decrease subjects' pain, pain interference and opioid use without changing our standard of care post-injury pain medication regimen. Enrolled subjects will be randomized to Fluoxetine or placebo at their index hospitalization.

NCT ID: NCT06046833 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

Start date: January 8, 2024
Phase: N/A
Study type: Interventional

A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.

NCT ID: NCT06046820 Recruiting - Clinical trials for Generalized Arterial Calcification of Infancy

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Start date: November 5, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

NCT ID: NCT06046729 Recruiting - Clinical trials for Hidradenitis Suppurativa

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start date: October 23, 2023
Phase: Phase 2
Study type: Interventional

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

NCT ID: NCT06046651 Recruiting - Sexual Dysfunction Clinical Trials

Blood Specimen Collection For Laboratory Assay Research

Start date: August 16, 2023
Phase:
Study type: Observational

To collect lab data from capillary and venous blood specimens for use in analytical research studies to support the development and validation of laboratory procedures.

NCT ID: NCT06046560 Completed - Diabetes Clinical Trials

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

DRIVE
Start date: March 22, 2021
Phase: Phase 4
Study type: Interventional

A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.

NCT ID: NCT06046495 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Start date: November 29, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations. Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations.